Claim: The FDA commissioner Marty Mackey has tweeted more about cracking down on compounded GLP-1 medications than about diabetes or heart disease during his tenure.
Verdict: Unverified (42% confidence)
Explanation: The search results provide evidence that FDA Commissioner Marty Makary has been actively involved in addressing issues related to compounded GLP-1 medications. Sources such as the FDA's official announcements and statements from Makary himself does not directly address his focus on cracking down on these medications (FDA.gov, CNBC, McDermottPlus). However, there is no specific evidence in the search results that compares the frequency of his tweets on this topic to those about diabetes or heart ...